Warnings for the popular bloodthinner Xarelto failed to properly address the increased risk for serious & even fatal bleeding problems
Xarelto users have more gastrointestional bleeds and need more transfusions
Xarelto (rivaroxoaban) is an anticoagulant used by millions of Americans to reduce the risk of stroke, deep vein thrombosis (DVT), pulmonary embolism (PE), and other blood clot injuries. It has been prescribed to individuals with non-valvular atrial fibrillation, following knee and hip replacement surgery and to prevent recurrence of clots. Xarelto was introduced in 2011, as a joint product developed by Johnson & Johnson’s Janssen Pharmaceuticals subsidiary and Bayer Health Care.
While all blood thinners carry a risk of internal bleeding, Xarelto appears to be associated with a much greater risk than the manufacturers indicated in warnings provided for consumers and the medical community. In many cases, Xarelto bleeding problems cannot be controlled by physicians, due to the lack of an approved reversal agent. Johnson & Johnson and Bayer promoted Xarelto as a superior alternative to warfarin (Coumadin), which had been the go-to anticoagulation therapy for decades.
Xarelto warnings fail to properly address the increased risk for serious and even fatal bleeding problems, despite a substantial number of adverse event reports and other findings suggesting that individuals taking Xarelto have more gastrointestional bleeds and need more transfusions.
Xarelto injury and wrongful death claims are currently being filed by Lenze Moss in the Eastern District of Louisiana.